An analysis of eight RCTs in advanced NSCLC found that men had significantly greater survival with anti-PD-1, anti-PD-L1, or anti-CTLA-4 monotherapy, whereas females benefited more from combined anti-PD-(L)1 and chemotherapy. Here, CD274 is linked to non-small cell lung carcinoma.